Aakaar Medical Technologies Limited · NSE:AAKAAR
Aakaar Medical Technologies — FY2026 Earnings Presentation
43 slides from Aakaar Medical Technologies's earnings presentation, May 15, 2026
Slide 1: Cover letter to National Stock Exchange
Aakaar Medical Technologies Limited (formerly: Aakaar Medical Technologies Pvt.Ltd.) A-801, Heritage Plaza, Teli Gali Cross Road Andheri (East), Mumbai – 400 069 INDIA Mob: + 91 9820317468 E-mail: info@aakaarmedical.in CIN No.: L74900MH2013PLC244717 www.aakaarmedical.in GST No: 27AALCA7587Q1ZK May 1
Slide 2: Aakaar announces H2 & FY2025-26 Results
Aakaar Medical Technologies Ltd. announces H2 & FY2025-26 Results Strongest H2 - Delivered as promised; Impact of tightened and disciplined financial approach Mumbai, May 15th, 2026: Aakaar Medical Technologies Ltd. (NSE: AAKAAR) today announced the unaudited financial results for the half year ende
Slide 3: About Aakaar Medical Technologies Limited
ABOUT AAKAAR MEDICAL TECHNOLOGIES LIMITED [formerly Aakaar Medical Technologies Pvt.Ltd.] Company contact Investor Relations Team Mr. Anoopkumar Pillai, Soumya Chhajed Company Secretary & Compliance Officer Email- soumya@goindiaadvisors.com A-801, Heritage Plaza, Teli Gali Cross Road Mobile: +91-861
Slide 4: Aakaar Medical Technologies Limited
INDIA'S 1ST MEDICAL AESTHETIC COMPANY · NSE LISTED Aakaar Medical Technologies Limited Investing in & Building the Future of Medical Aesthetics INVESTOR PRESENTATION 15th May 2026
Slide 5: Disclaimer
Disclaimer This presentation contains certain “forward looking statements” that are based on current expectations, assumptions, estimates and projections about the business, financial performance, industry trends and markets in which we operate. Such statements include, but are not limited to, those
Slide 6: Company at a Glance
Company at a Glance (Details For the Period FY25-26) 14.8% INR 67 Cr. INR 16 Cr 6300 + & Revenue up 8.6% Cash and Cash Customers YoY ROCE & ROE 17.1% Equivalents INR 11 Cr. INR 6.63 Cr 146 PAT up 10% YoY EBITDA up 12% YoY With an uptick of SKUs With an uptick of 42 bps 16 bps in margin to in margin
Slide 7: Resilience amidst all the odds – PAT positive since 10 years
Resilience amidst all the odds – PAT positive since last 10 years All values in INR Cr. Profit After Tax 6.63 6.0 2.2 2.4 2.0 1.7 1.8 1.8 0.8 0.5 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 Industry India Banking stress IL&FS COVID-19 COVID 2nd Ukraine Recovery Wide demonetization Startup defa
Slide 8: Comprehensive Business Segments of Aesthetics Products, Devices & Device Consumables
Comprehensive Business Segments of Aesthetics Products, Devices & Device Consumables Key Business Segments (Professional In-clinic & At Home Use) A. Aesthetics Products B. Aesthetics Devices & Device Consumables Clinical and aesthetics devices & device Products for hair care, skin care & injectables
Slide 9: Recurring, High growth, Margin accretive and Asset light
Recurring, High growth, Margin accretive and Asset light Revenue Engine – Product-led; Recurring Annuity based business o Aesthetic Products occupying 89% + 4% of Device Consumables are giving recurring business o Transition to Owned brands (37%) build margins and defensibility o Customers expansion
Slide 10: Growth Levers
Growth Levers All values in INR Cr. Launching high growth brands Increasing number of doctors per brand (SKU wise split) 146 4671 4403 147 4131 140 3443 121 2257 FY22 FY23 FY24 FY25 FY26 SKU 1-3 1969 2972 3571 3482 3404 SKU 4-6 177 370 419 582 623 SKU 7-10 80 77 106 222 350 SKU 11-20 27 22 33 102 20
Slide 11: Strong Segment Growth across Entire Spectrum of Aesthetics Solutions
Strong Segment Growth across Entire Spectrum of Aesthetics Solutions All values in INR Cr. Revenue growth over last 3 years Injectable & Aesthetics Devices & Professional Homecare for Skin Professional Contouring Device Consumables Skincare & Hair Haircare 11 11 18 7 20 5 8 6 9 1 FY23 FY26 FY23 FY26
Slide 12: Strong Brand Portfolio – Top 10 Products
Strong Brand Portfolio – Top 10 Products FY26 Revenue Product Product Segment (INR Cr)* Top 10 own products contribution as % share of revenue from operations Inno Exfo Lightening Professional Skin Care 13.04 FY 26 27% Siax Injectables & Contouring 3.51 FY 25 24% TUBELiTE GFC 360 Kit Injectables & C
Slide 13: Expanding Market Reach: Serving Medical Professionals Nationwide
Expanding Market Reach: Serving Medical Professionals Nationwide + 6,300 100 1,000 52 + + + Dermats & Clinics MR executives Pharmacies Stockists Reduced reliance on The company's strategy of using doctor-dispensed products has successfully top 10 customers expanded its reach to a larger market, bene
Slide 14: PAN India Distribution Strength Reflected in Geographical Reach
PAN India Distribution Strength Reflected in Aakaar’s Geographical Reach Punjab 6.1% INR 3.6 Cr Delhi 6.8% INR 6.8 Cr Aakaar’s nation-wide presence ensures reliable 5.6% Haryana Uttar Pradesh 7.9% INR 3.4 Cr INR 4.9 Cr supply, with ~84% of company’s revenue coming from 4.3% Gujarat INR 2.5 Cr its to
Slide 15: Robust Distribution Network for FY 25-26
Robust Distribution Network for FY 25-26 Strategic Nationwide Distribution Backbone Aakaar Medical (Novacare-CFA - Aakaar Medical (Andheri Self Bhiwandi & Panchkula) Warehouse) ❑ Pan-India Reach, Zero Capex: National warehousing network through PISPL earlier & now Novacare delivers Distribution Mode
Slide 16: Strategic Shift post Listing
02 Strategic Shift post Listing Impact of Tightened and disciplined financial approach
Slide 17: Delivered as promised – Plan of Action during H2FY26
Delivered as promised – Plan of Action during H2FY26 41.64 10.93 6.96 6.26 6.00 7.42 5.55 25.32 -0.78 209 188 180 167 0.02 H1FY26 H2FY26 Jun-25 Sep-25 Dec-25 Mar-26 H1FY26 H2FY26 H1FY26 H2FY26 Revenue (INR Cr) EBITDA (INR Cr) PAT (INR Cr) Debtors No of Days No of Months H1FY25 H1FY25 H1FY25 Action p
Slide 18: Robust Financial Performance YoY
Robust Financial Performance YoY Revenue (INR Cr) EBITDA (INR Cr) PAT(INR Cr) 42 11 7 34 8 6 H2FY25 H2FY26 H2FY25 H2FY26 H2FY25 H2FY26 67 7 11 62 10 6 FY25 FY26 FY25 FY26 FY25 FY26 Investor Presentation - 2026 Numbers rounded off 15
Slide 19: Half year ending FY26
Half year ending FY26 All values in INR Cr. Key Financial Performance H2FY26 H1FY26 H-O-H H2FY25 Y-O-Y Revenue from operations 41.6 25.3 64.4% 33.8 23.1% EBITDA 10.95 .02 546.5 % 8.33 31.45% EBITDA Margin 26.32 % 0.07% +2625 bps 24.64 % 168 Bps Turnaround PAT 7.4 (0.8) 5.6 32.1% to Profit PAT Margin
Slide 20: Statement of Profit and Loss
Statement of Profit and Loss Particulars FY23 FY24 FY25 FY26 All values in INR Cr. Revenue from operations 32.8 46.1 61.6 66.9 Other income 0.1 0.2 0.2 0.8 Total Income 32.9 46.3 61.8 67.7 COGS 15.0 20.9 26.2 28.20 Gross Profit 17.8 25.2 35.6 39.5 Margin 54.2% 54.6% 57.6% 59.34% Employee benefits ex
Slide 21: Balance Sheet Items
Balance Sheet Items All values in INR Cr. Particulars FY23 FY24 FY25 FY26 Particulars FY 23 FY 24 FY25 FY26 Equity and Liabilities Non-Current Assets Property, Plant & Equipment 0.4 0.3 0.2 0.1 Shareholders’ funds (PPE) a. Share capital 0.7 0.7 10.4 14.2 0.5 Intangible assets 0.01 0.01 0.01 b. Reser
Slide 22: Four Launches. One Strategy. Dominant Aesthetics Ecosystem.
The Big Picture Four Launches. One Strategy. Dominant Aesthetics Ecosystem. LETYBO® SAYPHA® VM CORP. XOMAGE NEUROMODULATOR DERMAL FILLER REGENERATIVE SUITE PLANT EXOSOMES US FDA-approved botulinum Austrian HA filler with USFDA 3-product Italian exosome Korean plant exosome toxin from Korea. Replaces
Slide 23: Consistent Product Launch
Consistent Product Launch Maxwave Devices Fotofinder DRS1512 Skin/Hair Extreluxe Nucleotide Consumables Etrelume Lyftox Medifacial Tinefcon Launch 2010 2011 2013 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Year In-House Product Imported Products Investor Presentation - 2026 20
Slide 24: Focused on strengthening doctor skills
Focused on strengthening doctor skills The Program is Designed to Train and Certify Practicing Dermatologists & Students on theory & practical knowledge of: + 5,000 MICA 129 1,134 Dermal Fillers Threads 23 Toxins (Masterclasss in Contouring Aesthetics) Dermats & Clinics Pharmacies Conducted under tu
Slide 25: Creating market through consistent trainings & workshops
Creating market through consistent trainings & workshops + 5,000 129 1,134 23 Dermats & Clinics Pharmacies • Conducted workshops to train Dermatologist & Cosmetic practitioners • MICA, hands-on workshop is conducted across Tier-I & II cities to provide training to the practitioners • Participated in
Slide 26: XELIX
6300+ XELIX 146 India-First Doctors Brands Product SKUs In Our Network Offered Across Portfolio HAIR | SKIN | BODY Doctor-Owned, Doctor- 16 Active Clinics 20+ Brands Portfolio Operated India's First Doctor-Owned, WHAT XELIX OFFERS Doctor-Operated Medical Aesthetics Platform Clinical Foundation Propr
Slide 27: Growth Journey
GROWTH JOURNEY From launch to India's largest standardized aesthetics network FY26 FY27 Future FY25–26 Mid-Term Expansion 50 Clinics 100+ Clinics 500 Clinics Hair First Scale & Skin Multi-Vertical • Expand into skin aesthetics & medi- • Body aesthetics added as third • Launch with hair restoration f
Slide 28: Our Doctor Network
OUR DOCTOR Doctor Specialty Experience Location NETWORK Dr Kavish Chouhan Dermatologist 12+ Years Delhi Every Xelix partner is a rigorously vetted, practising physician. No Dr V S Rathore Plastic Surgeon 18+ Years Kolkata franchisees. No middlemen. Patients are always in expert hands. Dr Gulhima Aro
Slide 29: Why Xelix Wins
WHY XELIX WINS Six structural advantages that create a defensible, compounding business.. Large, Underpenetrated TAM Unfair Advantage at Launch Asset-Light Compounding India’s medical aesthetics market is large, fast- Aakaar’s 6300+ doctor relationships and 146- DODO model = zero capex per clinic. E
Slide 30: Experienced and Passionate Leadership Team
Experienced and Passionate Leadership Team Founder & MD CEO & Executive Director Chief Financial Officer Company Secretary Mr. Dilip Meswani Dr. Rahul Sawakhande Mr. Rakesh Parekh Mr. Anoopkumar Pillai o B.Sc. from the University of o Bachelor of Medicine and Surgery o Fellow Member of ICSI and hold
Slide 31: Supported by Strong Directors and Management Team
Supported by Strong Directors and Management Team Independent Director Independent Director National Sales Head National Sales Head Mr. Rajendra Dhandhukia Mr. Deepanjan Periwal Mr. Saurabh Chamoli Mr. Deepak Sharma o B.Sc. from the University of Bombay, o Chartered Accountant and holds a o National
Slide 32: Annexure
~~ enhancing life through technology. 03 cD San S x cD = c <x
Slide 33: Aakaar is Uniquely Positioned in a Competitive Market
Aakaar is Uniquely Positioned in a Competitive Market Types of Offerings Types of Products and/or Devices Offered Facial Body Contouring Tattoo Products Devices Hair Removal Aesthetics & Injectables Removal Investor Presentation - 2026 30
Slide 34: Aakaar's Complete Range of Aesthetics Products
A. Aesthetics Products B. Aesthetics Devices & Device Consumables A. Aakaar’s Complete Range of Aesthetics Products Professional Skin Care Range Addresses diverse skin concerns, combining science and innovation to deliver outstanding results. Includes peels, medi-facials, etc Professional Hair Care
Slide 35: Aakaar Brand: Extensive Range of Aesthetics Product SKUs
Aakaar Brand: Extensive Range of 54 Aesthetics Product SKUs FY 2025 FY 2026 Company’s 11 years of experience ensures their home- grown aesthetic products deliver premium quality and INR 19.8 Cr INR 24.57 Cr 37% superior results Revenue from own brand products Revenue from own brand products Professi
Slide 36: Imported/Third Party Brands: Rights to Distribute Aesthetics Product SKUs
Imported/Third Party Brands: Rights to Distribute 78 Aesthetics Product SKUs FY 2025 FY 2026 Providing Indian consumers with exclusive access to renowned global skincare and aesthetics brands INR 33.2 Cr INR 42.39 Cr 63% Revenue from IMP brand products Revenue from IMP brand products Introducing inn
Slide 37: Strengthening Products Portfolio through In-licensing Tie-ups FY 25-26
Strengthening Products Portfolio through In-licensing Tie-ups with Reputable International Brands as on FY 25-26 Aakaar’s in-licensing agreements and collaborations with renowned international aesthetic brands allow them to distribute select high-demand products across India, currently contributing
Slide 38: Strengthening Products Portfolio through In-licensing Tie-ups FY 26-27
Strengthening Products Portfolio through In-licensing Tie-ups with Reputable International Brands FY 26-27 Aakaar’s in-licensing agreements and collaborations with renowned international aesthetic brands allow them to distribute select high-demand products across India, currently contributing to 70%
Slide 39: Aesthetics Devices & Device Consumables
B. Aesthetics Devices & Device Consumables Range of Devices and Device Consumables for Innovative Aesthetics Solutions Aakaar’s aesthetic devices utilize cutting-edge technology tailored to diverse skincare and haircare needs, with each device Brands Offered engineered for precision, safety and effi
Slide 40: From Concept to Commercial Release: Product Development Journey
From Concept to Commercial Release: Aakaar’s Product Development Journey Research & Ideation – Concept Development Feasibility Prototype Development 1 Month – 1 Month Analysis – 1 Month – 2 Months ✓ Market research ✓ Select promising ideas ✓ Assess technical feasibility ✓ Create prototypes for testi
Slide 41: Ideation to Launch for Imported Products
Ideation to Launch for Imported Products Research & Ideation – Identification – 1 Feasibility Prototype Development 1 Month Month Analysis – 1 Month – 1 Month ✓ Market research ✓ Evaluate Idea ✓ Assess technical feasibility ✓ Import product Samples ✓ Identify trends and consumer needs ✓ Conduct Conc
Slide 42: Key Clients
Key Clients Aakaar’s clients encompass a wide range of professionals and corporates, from individual doctors to renowned dermatology clinics, ensuring personalized and high-quality care Some of Aakaar’s esteemed clients include: 01 One of the largest chains of slimming, beauty, and 05 Clinic with 27
Slide 43: Thank You
Thank You For further information, please get in touch with: Company Contact Anoopkumar Pillai Company Secretary +91 84528 44024 Investor Relations Contact Contact Name soumya@GoIndiaadvisors.com +91 8619707750 40
Aakaar Medical Technologies — FY2026 Earnings Presentation on 6ix